Dewpoint Therapeutics IncDewpoint Therapeutics Inc and Mitsubishi Tanabe Pharma Corporation have formed a collaboration, valued at up to $480m, to develop a novel small molecule condensate modulator for ALS, leveraging groundbreaking European research in condensate biology.
Tag Archive for: Mitsubishi Tanabe
Draupnir Bio ApSTargeted protein degradation Draupnir Bio Aps has raised further €12m in an equitiy investment to advance its preclinical pipeline.